A VHL‐based PROTAC, utilising MRTX849 as a covalent ligand for KRAS G12C, was subsequently developed, which was demonstrated to induce KRAS degradation and inhibit MAPK signalling in various KRAS G12C‐mutant lung cancer cell lines, although its anti‐proliferative effects were not significantly enhanced compared to MRTX849 alone [76]. Here, KRAS is linked to lung cancer.